In a recent study by Pichet Binette and colleagues, it was observed that amyloid-related increases in soluble phosphorylated tau (p-tau) at epitope 217 in CSF was associated with cognitive decline and faster accumulation of tau aggregates in the early stages of AD, especially in regions that are functionally connected to areas where tau pathology started (Pichet Binette et al., 2022). The gene discussed is MAPT; the disease is Alzheimer disease.